证券代码：000590 证券简称：启迪药业 公告编号：2025-024 启迪药业集团股份公司 关于控股股东所持公司股份被司法拍卖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、2025 年 7 月 15 日，启迪药业集团股份公司（以下简称"公司"或"启迪 药业"）从京东网司法拍卖平台（网址：http://sifa.jd.com/）拍卖结果显示 获悉，公司控股股东启迪科技服务有限公司（以下简称"启迪科服"）持有的公 司 58,606,962 股股票均已拍卖成交（目前尚未收到控股股东及法院的正式确认 文件），启迪科服持有公司的 58,606,962 股股份网拍阶段已结束，最终成交以 北京金融法院出具的裁定为准。该部分股份目前尚未过户完成。 2、若本次股份拍卖全部过户完成，启迪科服所持公司股份将发生权益变动 数量为 58,606,962 股，占公司总股本的 24.47%，将可能导致公司控股股东及实 际控制人或将发生变更。请投资者注意相关风险。 3、若本次司法拍卖事项完成并股权变更过户后，湖南赛乐仙管理咨询服务 合伙企业（有限合伙）将持 ...

启迪药业（000590）公告，预计2025年1月1日至2025年6月30日归属于上市公司股东的净利润为亏损 1900万元-1500万元，上年同期为亏损2339.46万元；扣除非经常性损益后的净利润为亏损2500万元-2000 万元，上年同期为亏损2438.9万元；基本每股收益为亏损0.0793元/股-0.0626元/股，上年同期为亏损 0.0977元/股。公司近两年来受市场环境等因素影响，营业总收入下滑，部分原辅材料价格上涨，导致 整体毛利率及盈利水平下降。 ...

[Tus-Holdings Pharmaceutical Group Co., Ltd. 2025 Semi-Annual Performance Forecast](index=1&type=section&id=Tus-Holdings%20Pharmaceutical%20Group%20Co.%2C%20Ltd.%202025%20Semi-Annual%20Performance%20Forecast) [I. Expected Performance for the Current Period](index=1&type=section&id=I.%20Expected%20Performance%20for%20the%20Current%20Period) The company anticipates continued losses in the first half of 2025, with net loss attributable to shareholders expected to narrow from **23.3946 million yuan** in the prior year to **15 million - 19 million yuan**, indicating a reduced loss margin Performance Forecast for the Current Period | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company (yuan)** | Loss: **15,000,000 - 19,000,000** | Loss: **23,394,600** | | **Net Profit After Deducting Non-Recurring Gains and Losses (yuan)** | Loss: **20,000,000 - 25,000,000** | Loss: **24,389,000** | | **Basic Earnings Per Share (yuan/share)** | Loss: **0.0626 - 0.0793** | Loss: **0.0977** | [II. Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The financial data in this performance forecast represents the company's preliminary estimates and has not been audited by an accounting firm - The financial data in this performance forecast is a preliminary estimate and has not been audited by an accounting firm[3](index=3&type=chunk) [III. Explanation of Performance Changes](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Changes) The company attributes the continued losses in the first half to two core factors: a decline in total operating revenue due to market conditions and increased raw material prices compressing overall gross margin - The company attributes the net profit loss to a decline in total operating revenue caused by market conditions over the past two years[4](index=4&type=chunk) - Rising prices of some raw and auxiliary materials are another reason for the decline in overall gross margin and profitability[4](index=4&type=chunk) [IV. Risk Warning and Other Related Information](index=1&type=section&id=IV.%20Risk%20Warning%20and%20Other%20Related%20Information) The company advises investors that this performance forecast is based on preliminary estimates, and the final financial data will be subject to the 2025 semi-annual report, urging caution regarding investment risks - This performance forecast represents preliminary data estimated by the company's finance department and is not the final result[5](index=5&type=chunk) - The final accurate financial data will be disclosed in the company's 2025 semi-annual report, reminding investors to be aware of investment risks[6](index=6&type=chunk)

New Stock Issuance - Shanda Electric (Stock Code: 301609) issued at a price of 14.66[1] - Jiyuan Group (Stock Code: 732262) issued at a price of 10.88[1] Market Alerts - Jichuan Pharmaceutical (Stock Code: 600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - The last trading day for Tuisan Jinguang (Stock Code: 600190) is July 14, 2025, with 4 trading days remaining[1] - The last trading day for Tuisan Jinjing (Stock Code: 900952) is also July 14, 2025, with 4 trading days remaining[1] Abnormal Fluctuations - *ST Zitian (Stock Code: 300280) reported severe abnormal fluctuations on July 10, 2025[1] - *ST Yushun (Stock Code: 002289) reported abnormal fluctuations on July 11, 2025[1] Other Notable Announcements - Longyuan Green Energy (Stock Code: 603185) announced on July 11, 2025[1] - Kedi Pharmaceutical (Stock Code: 000590) announced on July 14, 2025[1]

一、股票交易异常波动的情况 启迪药业集团股份公司（以下简称"公司"）股票（证券简称：启迪药业， 证券代码：000590）连续 3 个交易日（2025 年 7 月 9 日至 7 月 11 日）收盘价格 涨幅偏离值累计达到 28.14%，根据《深圳证券交易所股票上市规则》的有关规 定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 证券代码：000590 证券简称：启迪药业 公告编号：2025-022 启迪药业集团股份公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 针对公司股票交易异常波动，公司对有关事项进行了核查，并致函公司控股 股东启迪科技服务有限公司（以下简称"启迪科服"）等，有关核查情况如下： 大影响的未公开重大信息； 筹划阶段的重大事项； 在买卖公司股票的情形。 三、不存在应披露而未披露信息的说明 和巨潮资讯网（www.cninfo.com.cn），公司所有信息均以在上述指定媒体披露 的信息为准，请广大投资者理性投资，注意风险。 特此公告。 启迪药业集团股份公司 董事会 本公司董事会确认，公司目前没有任何根据《深圳证券交易所股票上市规则》 ...

证券代码：000590 证券简称：启迪药业 公告编号：2025-022 启迪药业集团股份公司 股票交易异常波动公告 三、不存在应披露而未披露信息的说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 启迪药业集团股份公司（以下简称"公司"）股票（证券简称：启迪药业， 证券代码：000590）连续 3 个交易日（2025 年 7 月 9 日至 7 月 11 日）收盘价格 涨幅偏离值累计达到 28.14%，根据《深圳证券交易所股票上市规则》的有关规 定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 针对公司股票交易异常波动，公司对有关事项进行了核查，并致函公司控股 股东启迪科技服务有限公司（以下简称"启迪科服"）等，有关核查情况如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道可能或已经对本公司股票交易价格产生较 大影响的未公开重大信息； 3、公司目前经营情况及内外部经营环境未发生重大变化； 4、公司、控股股东不存在关于本公司应披露而未披露的重大事项，或处于 筹划阶段的重大事项； 5、股 ...

Market Review - The CITIC Pharmaceutical Index increased by 1.80%, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 CITIC first-level industry indices [5] - The top ten stocks by increase this week include Frontier Biologics-U, Medici, Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and others, with Frontier Biologics-U leading at 41.43% [4][5] - The bottom ten stocks by decrease include ST Weiming, Shenzhou Cell, and Shuotai Shen, with ST Weiming dropping by 18.51% [4][5] Overall Viewpoint and Investment Themes - The current valuation of the pharmaceutical sector is at a low point, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company remains optimistic about the growth of the pharmaceutical industry by 2025, driven by macroeconomic factors and the demand from major categories [9] - In the innovative drug sector, there is a shift from quantity logic to quality logic, focusing on differentiated domestic and international pipelines. The company suggests paying more attention to products and companies that can ultimately realize profits [9] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and the home medical device market is expected to benefit from subsidy policies. The company highlights the potential for import substitution and growth in the orthopedic sector post-collection [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas investment and a bottoming out in domestic investment, with a potential return to high growth by 2025 [9] - The pharmaceutical industry is anticipated to enter a new growth cycle, with a focus on specialty raw materials and the expiration of patents leading to new growth opportunities [9] Industry and Company Events - The company highlights the innovative layout of traditional Chinese medicine enterprises, with several products in clinical II and III phases, including those targeting chronic insomnia and primary acute gouty arthritis [29][30] - Yunnan Baiyao has several drugs in various clinical stages, including those for prostate cancer and other conditions, indicating a robust pipeline [16][19] - The company emphasizes the importance of the blood products sector, which is expected to see significant growth due to relaxed approval processes and increased production capacity [14] - The innovative drug pipeline of Yiling Pharmaceutical focuses on cardiovascular, respiratory, and endocrine diseases, with multiple drugs in clinical trials [20][21]

Market Overview - A-shares experienced a collective rise on July 10, with the Shanghai Composite Index surpassing the 3500-point mark, closing at 3509.68 points, up 0.48% [1] - The Shenzhen Component Index rose 0.47% to close at 10631.13 points, while the ChiNext Index increased by 0.22% to 2189.58 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 149.42 billion yuan, a slight decrease of 11 billion yuan compared to the previous day [1] Sector Performance - The majority of industry sectors saw gains, with real estate development, engineering consulting services, real estate services, cement and building materials, coal, small metals, diversified finance, and steel industries leading the increases [1] - Conversely, the jewelry, shipbuilding, and manufacturing sectors experienced declines [1] Stock Movement - A total of 2947 stocks rose, with 69 hitting the daily limit up, while 2279 stocks fell, with 14 hitting the daily limit down [1] - The market showed signs of volatility, with significant fluctuations observed during the trading day, particularly in blue-chip stocks such as banks, insurance, and real estate [1] Investment Trends - Market focus on sectors experiencing a turnaround, particularly in photovoltaic, lithium battery, and real estate concepts, with significant price increases in silicon wafer prices ranging from 8% to 11.7% due to upstream silicon material price hikes [2] - Despite positive technical indicators, including a bullish engulfing pattern in the Shanghai Composite Index, the overall buying strength remains insufficient, indicating caution in stock selection is necessary [2] Company Spotlight - Xiangguo's stock performance was notable, with 86 out of 147 stocks rising, including Qidi Pharmaceutical, which hit the daily limit up after a previous gain of over 9% [3] - Qidi Pharmaceutical's main business includes "Guhang Yangshengjing" series products and traditional Chinese medicine, reporting a net profit of -16.26 million yuan for Q1 2025, a year-on-year decline of 96.23% [3] - The company is preparing for a potential change in control due to the auction of 24.47% of shares held by its controlling shareholder, and it has signed a strategic cooperation agreement to develop a traditional Chinese medicine health and wellness tourism base [3]

Core Viewpoint - The A-share market shows a mixed performance with 476 stocks breaking through the five-day moving average, indicating potential investment opportunities in certain sectors [1] Group 1: Market Overview - As of 10:29 AM, the Shanghai Composite Index is at 3432.93 points, below the five-day moving average, with a fluctuation of 0.25% [1] - The total trading volume of A-shares today is 693.146 billion yuan [1] Group 2: Stocks with Significant Deviation - The stocks with the largest deviation from the five-day moving average include: - Morningstar Aviation (晨曦航空) with a deviation of 15.14% and a price increase of 19.99% [2] - Qifeng Precision (七丰精工) with a deviation of 11.69% and a price increase of 15.15% [2] - Awatech (阿为特) with a deviation of 10.02% and a price increase of 14.90% [2] - Other notable stocks with significant price increases and deviations include: - Xiongtai Technology (雄帝科技) with an 11.52% increase and an 8.85% deviation [2] - Songsheng Co. (崧盛股份) with a 10.85% increase and an 8.36% deviation [2] Group 3: Additional Stocks with Positive Performance - Other stocks showing positive performance and deviations include: - Lijun Co. (利君股份) with a 9.97% increase and a 7.69% deviation [2] - Xiangyu Medical (翔宇医疗) with a 10.41% increase and a 7.66% deviation [2] - Chengfei Integration (成飞集成) with a 10.00% increase and a 7.58% deviation [2]

证券代码：000590 证券简称：启迪药业 公告编号：2025-021 启迪药业集团股份公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、本次会议未出现否决提案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开的情况 1、召开时间： （1）现场会议时间：2025 年 6 月 26 日(星期四)下午 14:30。 （2）网络投票时间：2025 年 6 月 26 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 6 月 26 日上午 9:15—9:25,9:30—11:30 和 下午 13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的时间为 2025 年 6 月 26 日上午 9:15 至下午 15:00 期间的任意时间。 2、现场会议召开地点：湖南省衡阳市雁峰区罗金桥 1 号（雁峰区工业项目 集聚区）古汉中药有限公司一楼会议室。 3、召开方式：本次股 ...